Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of colesevelam HCl, Avandia (rosiglitazone maleate), or Januvia (sitagliptin) on glycaemic parameters and lipid profiles in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Trial Profile

Effects of colesevelam HCl, Avandia (rosiglitazone maleate), or Januvia (sitagliptin) on glycaemic parameters and lipid profiles in subjects with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Colesevelam; Rosiglitazone; Sitagliptin
  • Indications Hyperlipidaemia; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 15 May 2009 Results were presented in a DaiichiSankyo media release, and at the 18th Annual Meeting of the American Association of Clinical Endocrinologists.
    • 10 Apr 2009 Status changed from active, no longer recruiting to completed as reported by clintrial.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top